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Soluble epoxide hydrolase (sEH) is an emerging therapeutic target
in a number of diseases that have inflammation as a common
underlying cause. sEH limits tissue levels of cytochrome P450 (CYP)
epoxides derived from omega-6 and omega-3 polyunsaturated
fatty acids (PUFA) by converting these antiinflammatory mediators
into their less active diols. Here, we explored the metabolic effects
of a sEH inhibitor (t-TUCB) in fat-1mice with transgenic expression
of an omega-3 desaturase capable of enriching tissues with endog-
enous omega-3 PUFA. These mice exhibited increased CYP1A1,
CYP2E1, and CYP2U1 expression and abundant levels of the
omega-3–derived epoxides 17,18-epoxyeicosatetraenoic acid
(17,18-EEQ) and 19,20-epoxydocosapentaenoic (19,20-EDP) in insulin-
sensitive tissues, especially liver, as determined by LC-ESI-MS/MS.
In obese fat-1mice, t-TUCB raised hepatic 17,18-EEQ and 19,20-EDP
levels and reinforced the omega-3–dependent reduction observed
in tissue inflammation and lipid peroxidation. t-TUCB also pro-
duced a more intense antisteatotic action in obese fat-1 mice, as
revealed by magnetic resonance spectroscopy. Notably, t-TUCB
skewed macrophage polarization toward an antiinflammatory
M2 phenotype and expanded the interscapular brown adipose
tissue volume. Moreover, t-TUCB restored hepatic levels of Atg12-
Atg5 and LC3-II conjugates and reduced p62 expression, indicating
up-regulation of hepatic autophagy. t-TUCB consistently reduced
endoplasmic reticulum stress demonstrated by the attenuation of
IRE-1α and eIF2α phosphorylation. These actions were recapitu-
lated in vitro in palmitate-primed hepatocytes and adipocytes in-
cubated with 19,20-EDP or 17,18-EEQ. Relatively similar but less
pronounced actions were observed with the omega-6 epoxide,
14,15-EET, and nonoxidized DHA. Together, these findings identify
omega-3 epoxides as important regulators of inflammation and
autophagy in insulin-sensitive tissues and postulate sEH as a drug-
gable target in metabolic diseases.
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soluble epoxide hydrolase
Cytochrome P450 (CYP) epoxygenases represent the thirdbranch of polyunsaturated fatty acid (PUFA) metabolism (1).
CYP epoxygenases add oxygen across one of the four double bonds
of PUFA to generate three-membered ethers known as epoxides
(1). In the case of arachidonic acid, CYP epoxygenases convert this
omega-6 PUFA into epoxyeicosatrienoic acids (EETs), which act as
autocrine or paracrine factors in the regulation of vascular tone,
inflammation, hyperalgesia, and organ and tissue regeneration
(2, 3). In addition to omega-6s, CYP epoxygenases also convert the
omega-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) into novel epoxyeicosatetraenoic (EEQs) and epoxy-
docosapentaenoic (EDPs) acids, respectively (4, 5). These omega-
3–derived epoxides also exert salutary actions and are even more
effective and potent than omega-6–derived EETs (4–8).
Because the predicted in vivo half-lives of fatty acid epoxides
(EpFA) are in the order of seconds (9), drugs that stabilize their
levels by targeting the enzyme soluble epoxide hydrolase (sEH)
are currently under investigation. sEH is a cytosolic enzyme with
epoxide hydrolase and lipid phosphatase activities that catalyzes
the rapid hydrolysis of EETs, EEQs and EDPs by adding water
to these EpFA and converting them into inactive or less active
1,2-diols (10). Accordingly, inhibition of sEH exerts beneficial
actions in controlling vascular tone, inflammation, and pain, and
this strategy has shown its therapeutic potential for long-term
use in hypertension, diabetes, renal disease, organ damage, and
vascular remodeling (6, 9–12).
The aim of the present study was to investigate the potential
metabolic benefits of sEH inhibition in obesity. Specifically, this
study addresses the question as to whether sEH inhibition
increases the effectiveness of omega-3–derived epoxides in obese
adipose tissue and liver in the context of enriched omega-3 tissue
content. fat-1 mice with transgenic expression of the Caeno-
rhabditis elegans omega-3 fatty acid desaturase gene represent
a useful model to address this question because these mice have
abundant tissue omega-3 distribution from their embryonic stage
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and throughout their lives (13, 14). This study builds on previous
work by our laboratory demonstrating that fat-1 mice replicate
the protection against insulin resistance and hepatic inflam-
mation and steatosis observed in obese mice nutritionally
enriched with exogenous omega-3 PUFA (13, 15). The results of
the present investigation indicate that inhibition of sEH when
there is an increased content of omega-3 PUFA exerts a more
favorable role in counteracting the metabolic disorders associ-
ated with obesity. In addition, our findings expand focus to in-
clude EpFA to the protective actions described for those lipid
mediators derived from omega-3s through lipoxygenase- and
cycloxygenase-initiated pathways (i.e., resolvins, protectins, and
maresins) (16, 17).
Results
WT and fat-1 mice had similar body and epididymal white adi-
pose tissue (eWAT) weights under Chow conditions (Fig. S1A).
However, fat-1 mice exhibited smaller adipocyte size (Fig. S1B).
The administration of a high-fat diet (HFD) resulted in in-
creased adipocyte hypertrophy and extensive positive F4/80
staining (Fig. S1B). HFD-fed mice also displayed enhanced fi-
brosis (Fig. S1B). Compared with WT, fat-1 mice were more
resistant to HFD-induced obesity (body weight: 45.6 ± 0.8 vs.
49.7 ± 1.0 g, P < 0.01; eWAT weight: 1.5 ± 0.1 vs. 1.8 ± 0.1 g, P <
0.01) and showed reduced adipocyte size, macrophage infiltrate,
and fibrosis (Fig. S1B). Changes in adiposity, inflammation and
fibrosis were confirmed by morphometric analysis and by
assessing F4/80 expression by real-time PCR (Fig. S1B). fat-1
mice also showed reduced monocyte chemoattractant protein 1
(MCP-1) and increased CD206, IL-10, and macrophage galac-
tose-type C-type lectin 1 (MGL1) (Fig. S1C). These results were
confirmed in HFD-induced obese mice receiving omega-3 PUFA
through the diet (Fig. S1D). No changes in IL-6, IL-1β, arginase-
1 (Arg1), resistin-like molecule-α (RELMα), and Ym1 were
observed (Fig. S1D). eWAT from both lean WT and fat-1 mice
had constitutive expression of CYP epoxygenases with prefer-
ence for omega-3 PUFA (Fig. S1E). In response to the HFD,
CYP expression was repressed in WT mice, whereas CYP1A1
B
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Fig. 1. Tissue levels of omega-3–derived epoxy metabolites, 17,18-EEQ and
19,20-EDP, in fat-1 mice. (A) Schematic diagram of the CYP epoxygenation
pathway generating the omega-3 EpFA, 17,18-EEQ, and 19,20-EDP and
conversion into their inactive diols by sEH. (B) LC-ESI-MS/MS analysis of 17,18-
EEQ and 19,20-EDP levels in eWAT and liver from WT and fat-1 mice. (C)
Schematic diagram of the CYP epoxygenation pathway generating omega-6
EpFA (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) from arachidonic acid (AA)
and their inactivation by sEH. (D) LC-ESI-MS/MS analysis of omega-6 EpFA
levels in eWAT and liver. Results are mean ± SEM from WT (n = 28) and fat-1
(n = 20) mice. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 2. sEH overexpression and modulation of 17,18-EEQ and 19,20-EDP tissue
levels by the selective sEH inhibitor, t-TUCB. (A) Protein expression of sEH in
liver and eWAT from WT and fat-1 mice. Densitometry of sEH signals nor-
malized to β-actin is shown on the right. (B) LC-ESI-MS/MS analysis of omega-3
and omega-6 epoxides in liver from HFD-induced obese WT and fat-1 mice
receiving t-TUCB (10 μg/mL) for 16 wk. (C) LC-ESI-MS/MS analysis of inactive
diols in livers from obeseWT and fat-1mice receiving t-TUCB. (D) Hepatic ratios
of active metabolites to inactive diols. (E) Protein expression of sEH in liver and
eWAT from obese WT and fat-1 mice receiving t-TUCB. Densitometry of sEH
signals normalized to β-actin is shown below. Results are mean ± SEM fromWT
(n = 28) and fat-1 (n = 20) mice. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 3. Effects of t-TUCB on adipose tissue in obese fat-1 mice. (A) Body
weight curves for WT (n = 28) and fat-1 (n = 20) mice receiving a HFD and
treated with either placebo (Plb) or t-TUCB for 16 wk. (B) Representative MR
images of coronal sections. Total fat volume (C) and iBAT volume (D)
assessed by MRI analysis. (E) Representative photomicrographs of adipose tissue
sections stained with H&E (Top), F4/80 (Middle), and Sirius red (Bottom) and
adipocyte cross-sectional area, Sirius red staining, and F4/80 mRNA expression.
(Magnification: 200×.) (F) Malondialdehyde (MDA) concentration andMGL1 and
RELMα mRNA expression in adipose tissue. Results are mean ± SEM *P < 0.05,
**P < 0.01, and ***P < 0.001.
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was induced in fat-1 mice with no changes in CYP2E1 and
CYP2U1 (Fig. S1E).
Because—in addition to adipose tissue—the liver plays a piv-
otal role in metabolic homeostasis, we also examined the hepatic
phenotype of fat-1 mice. Consistent with our recent finding that
fat-1 mice are protected against HFD-induced hepatic in-
flammation and steatosis (13), HFD-fed fat-1 mice presented
lower serum ALT/AST and reduced F4/80 and Oil Red-O
staining (Fig. S2A). Moreover, HFD-fed WT mice exhibited a
unique hepatic pattern of CYP expression characterized by up-
regulation of CYP1A1, CYP2E1, and CYP2U1 (Fig. S2B). In
contrast, only CYP2U1 was up-regulated by HFD feeding in fat-
1 mice (Fig. S2B). A distinct pattern of CYP expression in re-
sponse to HFD was also detected in skeletal muscle (Fig. S2C).
Direct comparison of CYP expression among insulin-sensitive
tissues revealed that CYP2E1 and CYP2U1 are preferentially
expressed in the liver, whereas CYP1A1 appears as the major
isoform in muscle (Fig. S2D). The observation that changes in
CYP expression in HFD-fed mice in response to omega-3 en-
richment are tissue-dependent was confirmed in obese WT mice
receiving omega-3 PUFA through the diet (Fig. S3).
Because many CYP epoxygenases can form epoxides convert-
ing omega-3 PUFA into biologically active 17,18-EEQ and 19,20-
EDP metabolites (Fig. 1A), we next analyzed these epoxides by
liquid chromatography-electrospray ionization (LC-ESI)-MS/MS.
Both EPA-derived 17,18-EEQ and DHA-derived 19,20-EDP
were detected in eWAT and liver (Fig. 1B). Importantly, 17,18-
EEQ levels were significantly increased in eWAT and liver from
fat-1 mice (Fig. 1B). In these tissues, 19,20-EDP was also in-
creased in fat-1 mice and changes in this epoxide reached statis-
tical significance in eWAT (Fig. 1B). Unexpectedly, HFD
triggered omega-3–derived epoxides in the liver, especially in WT
mice (Fig. 1B). Increased tissue levels of omega-3–derived
epoxides were also seen in eWAT and liver from obese WT mice
after receiving an omega-3–enriched diet (Fig. S4A). On the
other hand, EETs regioisomers (5,6-EET, 8,9-EET, 11,12-EET,
and 14,15-EET), formed from arachidonic acid by CYP epoxi-
dation (Fig. 1C), were also detected in eWAT and especially in
liver (Fig. 1D). Hepatic EET levels were also increased by HFD
(Fig. 1D), an effect also seen in WT mice receiving an omega-3–
enriched diet (Fig. S4B). The fact that omega-3– and omega-6–
derived epoxides were more abundant in liver (Fig. 1 B and D)
was consistent with the presence of a higher content of PUFA in
this organ (Fig. S5A). Moreover, although the rate-limiting enzymes
involved in long-chain fatty acid desaturation (i.e., Δ5 and Δ6
desaturases) were constitutively expressed in liver, the expression of
Δ6 desaturase in eWAT was undetectable and residual at protein
(Fig. S5B) and mRNA (Fig. S5C) levels, respectively.
We next sought to establish the role of sEH, the key enzyme in
the inactivation of EpFA. Consistent with previous findings, the
sEH protein was preferentially expressed in liver (18) and slightly
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increased by HFD feeding (Fig. 2A). In fat-1 mice, HFD-feeding
also increased sEH expression in eWAT (Fig. 2A). Because in-
hibition of the sEH prevents the inactivation of EpFA by epoxide
hydration, we next analyzed the omega-3–derived epoxides in
mice treated with the selective sEH inhibitor, trans-4-{4-[3-(4-
trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid
(t-TUCB). Administration of t-TUCB to HFD-induced obese
mice resulted in increased 17,18-EEQ levels in liver (Fig. 2B)
and eWAT (Fig. S5D) from both WT and fat-1 mice. Tissue
levels of 19,20-EDP were increased in livers from fat-1 mice and
eWAT from WT animals (Fig. 2B and Fig. S5D). t-TUCB also
increased levels of EETs in liver and eWAT from both WT and
fat-1 mice, although the extent of stimulation was less pronounced
than that of 19,20-EDP (Fig. 2B and Fig. S5D). Hepatic levels of
19,20-DiHDPA, the inactive or less active 1,2-diol from 19,20-EDP,
as well as the respective EETs diols were significantly reduced by
t-TUCB in WT mice (Fig. 2C). No changes in diol levels were
observed in fat-1 mice (Fig. 2C). Of note, the hepatic ratios of
each active epoxide to the corresponding inactive diol were sig-
nificantly increased by t-TUCB (Fig. 2D). Compared with pla-
cebo, t-TUCB did not induce any significant effect on the hepatic
and adipose tissue levels of arachidonic acid, DHA and EPA
(Table S1). Coincident with previous findings (19), t-TUCB up-
regulated hepatic sEH protein expression (Fig. 2E).
Because sEH inhibition is associated with salutary effects, we
next assessed the metabolic actions of t-TUCB in mice with
HFD-induced obesity. As shown in Fig. 3A, t-TUCB did not
modify weight gain in WT mice or alter the resistance of fat-1
mice to become obese. Consequently, endpoint body weight was
only influenced by the fat-1 phenotype (Fig. S6A). Anatomical
7.0T magnetic resonance (MR) imaging analysis confirmed re-
duced total fat volume in fat-1 mice and absence of changes in
this parameter following t-TUCB treatment (Fig. 3 B and C and
Fig. S6B). Interestingly, interscapular brown adipose tissue
(iBAT) volume was increased in fat-1 mice treated with t-TUCB
(Fig. 3D and Fig. S6C). Despite the absence of changes in total
fat volume, t-TUCB significantly reduced adipocyte hypertrophy,
macrophage infiltration, and adipose tissue fibrosis in obese WT
mice (Fig. 3E). No further reduction in these adiposity param-
eters was observed in obese fat-1 mice receiving t-TUCB (Fig.
3E). These findings were confirmed by morphometric analysis
and the assessment of F4/80 mRNA expression (Fig. 3E). Changes
in adipose tissue fibrosis were also confirmed by Masson’s trichrome
staining (Fig. S6D). Of interest, t-TUCB significantly reduced lipid
peroxidation in fat-1 mice and up-regulated the expression of
MGL1 and RELMα in both WT and fat-1 mice (Fig. 3F).
The effects of t-TUCB on the liver are shown in Fig. 4.
t-TUCB effectively blocked HFD-induced hepatic macrophage
infiltration in WT mice, an effect that was more intense in fat-1
mice (Fig. 4A). Consistently, t-TUCB decreased hepatic IL-1β
and IL-6 expression (Fig. 4B), while up-regulating MGL1 and
CD206 (Fig. 4C). M2 polarization of hepatic macrophages was
more evident in fat-1 mice receiving t-TUCB (Fig. 4C). In ad-
dition to reducing inflammation, t-TUCB decreased the hepatic
lipid content and induced a synergistic antisteatotic action in
fat-1 mice, as detected by MR spectroscopy (Fig. 4D). Represen-
tative spectra are depicted in Fig. 4E. The reduction of liver weight
in fat-1 mice was not further decreased by t-TUCB (Fig. 4F).
Because dysregulation of autophagy is a critical component of
liver and eWAT dysfunction in obesity (20), we next investigated
the effects of sEH inhibition on autophagy and the emergence of
endoplasmic reticulum (ER) stress, insulin resistance, and lipid
deposition in obesity. Consistent with previous studies (21, 22),
HFD-induced obesity increased the activity of the molecular
indicators of autophagy, Atg12-Atg5, and LC3-II, in eWAT from
WT mice, effects that were reversed by t-TUCB treatment (Fig. 5
A and B). No changes in Atg12-Atg5 and LC3-II conjugates were
observed in fat-1 mice after HFD feeding, but LC3-II was re-
duced and p62 was increased by t-TUCB (Fig. 5 A and B). On the
other hand, in livers from WT mice, HFD-induced obesity was
associated with reduced Atg12-Atg5 and LC3-II levels, and these
markers of autophagy were restored by t-TUCB (Fig. 5 C and D).
Reduced autophagy was not observed in livers from fat-1 mice,
suggesting that these mice were already protected from HFD-
induced autophagy dysfunction (Fig. 5 C and D). Taken together,
and considering that Atg12-Atg5 and LC3-II conjugates are re-
quired for autophagosome formation and that the induction of
p62 levels indicates a lack of functional autophagic degradation
(23), our data suggest that sEH inhibition improves the
autophagy flux in obese insulin-sensitive tissues. Finally, consis-
tent with the view that autophagy is integrated to ER homeo-
stasis (20), t-TUCB administration resulted in reduced ER stress,
as shown by the attenuation of inositol-requiring enzyme 1α
(IRE-1α) and eukaryotic initiation factor 2 (eIF2α) phosphory-
lation in both eWAT and liver (Fig. 5 A and C). The extent of
suppression of ER stress by t-TUCB was roughly similar in WT
and fat-1 mice (Fig. 5 A and C).
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Fig. 6. In vitro effects of EpFA on glucose uptake,
autophagy, ER stress, and lipid accumulation in dif-
ferentiated 3T3-L1 adipocytes. (A) Scheme of the in
vitro experiments. Visible microscope images at days
0 and 8 of differentiation are shown. (B, Left) Glucose
uptake assessed by the 2-deoxyglucose assay in cells
incubated with vehicle or sodium palmitate (PA) alone
or in combination with 19,20-EDP (EDP) and t-TUCB for
30 min. (Right) Quantitation of endpoint glucose up-
take. (C) GLUT-4 and IRS-1 expression in cells exposed
to 19,20-EDP (Left) or 17,18-EEQ (Right) in the pres-
ence of PA. (D and E) Western blots (15% SDS/PAGE)
of Atg7, Atg12-Atg5, LC3-I/II, p62, phosphoIRE-1α
(p-IRE-1α), phosphoeIF2α (p-eIF2α), total eIF2α (eIF2α),
and α-tubulin in cells incubated with vehicle or PA
(0.5 mM) alone or in combination with t-TUCB (1 μM),
19,20-EDP (1 μM), 17,18-EEQ (1 μM), 14,15-EET (1 μM),
and DHA (1 and 10 μM) in the absence or presence
of the protease inhibitors E-64d/pepstatin A for 24 h.
(F) Representative photomicrographs of Oil Red-O–
stained cells incubated with the same conditions as D
and E. (Magnification: 200×.) The amount of Oil Red-O
retained is shown on the middle. Results are mean ±
SEM from three independent experiments assayed in
triplicate. *P < 0.05, **P < 0.005, and ***P < 0.001.
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To provide direct evidence linking omega-3 EpFA to auto-
phagy and ER stress, we next performed in vitro experiments in
adipocytes incubated with the saturated fatty acid palmitate,
a major contributor to lipotoxicity and insulin resistance (24). A
schematic diagram of the experimental in vitro procedure is
shown in Fig. 6A. Incubation of adipocytes with 19,20-EDP, the
most abundant omega-3 epoxide in eWAT, in the presence of
t-TUCB, stimulated glucose uptake in adipocytes (Fig. 6B).
Moreover, in these cells, 19,20-EDP and 17,18-EEQ induced
a concentration-dependent up-regulation of insulin receptor
substrate-1 (IRS-1) and glucose transporter-type 4 (GLUT-4)
(Fig. 6C). Interestingly, in the presence of t-TUCB, both 19,20-
EDP and 17,18-EEQ produced similar changes in autophagy to
those reported in vivo in eWAT from obese fat-1 mice receiving
t-TUCB (Fig. 6D). With t-TUCB on board, reduction of IRE-
1α and eIF2α phosphorylation in response to these omega-3
EpFA also paralleled that seen in vivo (Fig. 6D). In these
experiments, the omega-6 EpFA, 14,15-EET, and the non-
oxidized form of DHA were either ineffective or less active
than omega-3 EpFA in regulating authophagy and ER stress in
adipocytes (Fig. 6E). All compounds tested significantly re-
duced palmitate-induced accumulation of lipids in adipocytes,
with the EpFA being more potent than the nonoxidized form
of DHA (Fig. 6F). t-TUCB alone did not modify ER stress,
autophagy, and intracellular lipid levels (Fig. S6E).
Finally, we incubated hepatocytes with palmitate in the pres-
ence of EpFA and t-TUCB. As shown in Fig. 7A, incubation of
hepatocytes with 19,20-EDP and t-TUCB resulted in increased
autophagosome formation, as revealed by the disappearance of
LC3-I and its conversion to LC3-II by conjugation to phospha-
tidylethanolamine. This improvement in autophagy was mirrored
by a reduction in the phosphorylated forms of IRE-1α and
eIF2α, indicative of attenuated ER stress in hepatocytes (Fig.
7A). In these cells, 19,20-EDP also overrode palmitate-induced
accumulation of intracellular lipids (Fig. 7B). Similar actions on
intracellular lipid levels were observed with 17,18-EEQ as well as
with DHA and 14,15-EET, although this omega-6 EpFA was less
potent than the omega-3 epoxides (Fig. 7C). However, compared
with 19,20-EDP, 17,18-EEQ, DHA, and 14,15-EET were less
active in regulating autophagy and unable to modulate ER stress
in hepatocytes (Fig. 7D). Finally, we explored the effects of 17
(S)-HDHA, a lipid mediator acting as a precursor and marker of
the biosynthesis of the D-series resolvins and protectins derived
from DHA through the lipoxygenase pathway (16). This hy-
droxylated DHA-derived product also enhanced autophagy in
palmitate-treated hepatocytes (Fig. 7E), and reduced the accu-
mulation of intracellular lipids in palmitate-primed hepatocytes
(Fig. 7F). t-TUCB alone did not induce any change in the re-
sponse of hepatocytes to palmitate (Fig. 7 B and D).
Discussion
Special attention has been given to the effects of omega-3 PUFA
on the chronic “low-grade” inflammatory state driven by the
expansion of adipose tissue mass in obesity (15, 25). This per-
sistent inflammation in adipose tissue of obese individuals is
deleterious and increases the incidence of comorbidities, in-
cluding insulin resistance and nonalcoholic fatty liver disease,
a condition in which a recent systematic meta-analysis reported
the benefits of omega-3 PUFA therapy (26). In addition, our
understanding the recognized therapeutic values of omega-3s has
been challenged by the discovery that these fatty acids can be
converted to a novel class of proresolving lipid mediators (i.e.,
resolvins, protectins, and maresins) (reviewed in ref. 16). Indeed,
these proresolving mediators are able to counteract inflammation
and to prime the resolution process in obesity-induced non-
alcoholic fatty liver disease (17). A common feature of these
proresolving lipid mediators is that their biosynthesis from
omega-3 PUFA is initiated through the interaction of lip-
oxygenase and cyclooxygenase pathways, the two classic branches
of PUFA metabolism (16). Recent findings indicate that CYP
epoxygenases, the so-called third branch of PUFA metabolism,
can also convert omega-3 PUFA into bioactive lipid mediators
(1, 4, 5). Indeed, CYP1A1, CYP2E1, and CYP2U1 have been
described to generate a number of CYP-derived epoxides
(namely EEQs and EDPs) from omega-3 PUFA (4). In our
study, we used fat-1 mice as an optimal model of omega-3 en-
richment, in which the stabilization of CYP-derived epoxides by
a sEH inhibitor reinforced the omega-3–dependent reduction in
hepatic inflammation and intrahepatic lipid deposition. Taken
together, our findings expand to the metabolic field the initial
observation that an omega-3–rich diet in combination with
a sEH inhibitor exerts antihypertensive actions (6).
A salient feature of our study was that the sEH inhibitor re-
stored autophagy in livers from obese fat-1 mice. Defective
autophagy contributes to a variety of diseases, because efficient
sequestration and clearance of damaged cellular components in
stress conditions is crucial for cell homeostasis (27). Moreover,
consistent with the view that autophagy is a primordial cellular
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Fig. 7. In vitro effects of EpFA on autophagy, ER stress, and lipid accumu-
lation in primary hepatocytes. (A) Western blots (15% SDS/PAGE) of Atg7,
Atg12-Atg5, LC3-I/II, p62, phosphoIRE-1α (p-IRE-1α), phosphoeIF2α (p-eIF2α),
total eIF2α (eIF2α), and α-tubulin in hepatocytes incubated with vehicle or
palmitate (PA) (0.5 mM) in combination with 19,20-EDP (1 μM) and t-TUCB
(1 μM) in the absence or presence of E-64d/pepstatin A for 24 h. (B) Repre-
sentative photomicrographs of visible microscope (Top) and Oil Red-O–
stained (Middle and Bottom) hepatocytes exposed to vehicle or PA alone or
in combination with 19,20-EDP (EDP) and t-TUCB for 24 h. The amount of Oil
Red-O retained is shown on the right. (C) Representative photomicrographs
of Oil Red-O–stained hepatocytes exposed to either vehicle or PA alone or in
combination with 17,18-EEQ (EEQ, 1 μM), 14,15-EET (EET, 1 μM), DHA (1 and
10 μM), and t-TUCB (1 μM) for 24 h. (D) Western blot analysis of Atg7, Atg12-
Atg5, LC3-I/II, p62, p-IRE-1α, p-eIF2α, eIF2α, and α-tubulin in hepatocytes in-
cubated with the same conditions as in C. (E) Protein expression of LC3-I/II,
p62 and α-tubulin in hepatocytes incubated with vehicle or PA in combina-
tion with 17(S)-HDHA (1 μM). (F) Amount of Oil Red-O retained by hep-
atocytes in response to PA and 17(S)-HDHA. Results are mean ± SEM from
four independent experiments assayed in triplicate. *P < 0.01 and **P <
0.001 vs. vehicle. a, P < 0.05 vs. PA. (Magnification: 200×.)
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adaptive mechanism that mitigates ER-associated unfavorable
conditions in insulin-sensitive tissues (20), sEH inhibition in fat-1
mice was accompanied by an attenuated hepatic ER stress.
Down-regulation of ER stress was also seen in conjunction with
decreased autophagy in adipose tissue from fat-1 mice receiving
the sEH inhibitor, suggesting dissociation between these two
cellular processes in this tissue. Because inhibition of autophagic
function in adipose tissue is related to reduced fat mass and
improved insulin sensitivity (28), our findings in adipose tissue
can be regarded as beneficial in terms of lipid homeostasis and
metabolic control. A strong asset of our study was that we were
able to recapitulate the effects on autophagy and ER stress seen
in vivo following sEH inhibition, by exposing hepatocytes and
adipocytes in vitro to the omega-3 epoxides 19,20-EDP and
17,18-EEQ. Our findings are consistent with those reported by
Bettaieb et al., who showed attenuation of ER stress in adipose
and liver tissues in mice either receiving a sEH inhibitor or de-
ficient for sEH (29). However, our data cannot exclude other
EpFA, such as the case of arachidonic acid-derived EETs as
well as the potential implication of other oxidized lipid medi-
ators derived from omega-3 PUFA through the interaction of
lipoxygenase and cyclooxygenase pathway. Additionally, our data
cannot exclude the potential implication of nonoxidized DHA in
the observed favorable metabolic phenotype of fat-1 mice. In this
regard, although less potent than EpFA, DHA was active in our
cell bioassays. This finding is consistent with the reported bi-
ological properties of DHA (30) and with findings reported by
Caviglia et al. showing that DHA was able to rescue rat hepa-
toma cells from palmitate-induced ER stress (31). However,
these studies did not address whether the protective effects of
DHA were mediated by the parent nonoxidized molecule or by
any other DHA oxidized metabolite (30, 31).
In summary, the results of the present study demonstrate that
stabilization of omega-3 epoxides through inhibition of sEH
exerts beneficial actions in counteracting the metabolic disorders
associated with obesity. Of particular interest are the findings
demonstrating the ability of sEH inhibition to restore autophagy
in the liver with the consequent reduction of obesity-induced
liver ER stress. Our observations highlight the potentiality of
small bioactive lipid mediators to modulate autophagy, serving as
templates for the exploitation of this housekeeping cellular
process for therapeutic interventions against obesity and obesity-
related comorbidities, such as fatty liver disease.
Materials and Methods
Studies in fat-1 mice, hepatocytes and 3T3-L1 adipocytes, measurement of
2-deoxyglucose uptake, mRNA and protein expression, and histology and
immunohistochemistry analysis, MR imaging and spectroscopy, and LC-ESI-
MS/MS and gas chromatography analysis are described in detail in SI Materials
and Methods. The LC-MS/MS conditions used to profile the omega-3 and
omega-6 epoxides are described in Table S2 and a schematic diagram of the
experimental design of the study can be found in Fig. S7.
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